| Followers | 109 |
| Posts | 7722 |
| Boards Moderated | 0 |
| Alias Born | 11/23/2007 |
Wednesday, September 25, 2024 9:45:36 AM
HORRENDOUS SELLING
Recent KAPA News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2026 12:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2026 09:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2026 12:00:39 PM
- Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders • Business Wire • 06/04/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/26/2026 09:24:14 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/22/2026 08:12:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/22/2026 08:10:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 12:31:29 PM
- Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award • Business Wire • 05/14/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 09:20:50 PM
- Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI • Newsfile • 05/13/2026 09:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/11/2026 06:05:36 PM
- Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings • Business Wire • 05/08/2026 08:30:00 PM
- Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation • Business Wire • 04/15/2026 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/01/2026 08:50:59 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/01/2026 08:50:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 08:10:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 11:31:16 AM
- Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics • Business Wire • 03/02/2026 11:30:00 AM
- カイロス・ファーマ(Kairos Pharma, Ltd.)、Celyn Therapeuticsから臨床段階の腫瘍領域資産2件を戦略的に取得するタームシート締結を発表 • Business Wire • 02/27/2026 03:22:00 PM
- Kairos Pharma, Ltd. annonce la signature d'une feuille de modalités visant l'acquisition stratégique de deux actifs en oncologie clinique de Celyn Therapeutics • Business Wire • 02/26/2026 10:31:00 PM
- Kairos Pharma, Ltd. gibt Unterzeichnung einer Grundsatzvereinbarung über den strategischen Erwerb von zwei klinischen Onkologie-Assets von Celyn Therapeutics bekannt • Business Wire • 02/26/2026 10:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:00:33 PM
- Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics • Business Wire • 02/26/2026 12:00:00 PM
